Patents by Inventor Betty Lam

Betty Lam has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS
    Publication number: 20240140915
    Abstract: Disclosed are compounds of Formula (I): or pharmaceutically acceptable salts or solvates thereof, wherein R1, R3, X, Y, Z, and W are as defined herein. The compounds are, for example, inhibitors of WRN helicase and useful in treating a proliferative disease, such as cancer.
    Type: Application
    Filed: September 20, 2023
    Publication date: May 2, 2024
    Inventors: Shota Kikuchi, Betty Lam, Jason Green, Don Rogness, David Weinstein, Larry Burgess, Benjamin Horning, Kelsey Lamb, Zachary Owyang, Robert Malmstrom
  • PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS
    Publication number: 20240067612
    Abstract: Disclosed are compounds of Formula (I): or pharmaceutically acceptable salts or solvates thereof, wherein R1, R3, X, Y, Z, and W are as defined herein. The compounds are, for example, inhibitors of WRN helicase and useful in treating a proliferative disease, such as cancer.
    Type: Application
    Filed: July 5, 2023
    Publication date: February 29, 2024
    Inventors: Shota Kikuchi, Betty Lam, Jason Green, Don Rogness, David Weinstein, Larry Burgess, Benjamin Horning, Kelsey Lamb, Zach Owyang, Robert Malmstrom
  • FUSED HETEROAROMATIC PYRROLIDINONES
    Publication number: 20230295171
    Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein G, L1, L2, R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, pharmaceutical compositions containing them, and their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other disorders, diseases, and conditions for which inhibition of SYK is indicated.
    Type: Application
    Filed: January 12, 2023
    Publication date: September 21, 2023
    Inventors: Yasuyoshi Arikawa, Benjamin Jones, Betty Lam, Masashi Takahashi, Christopher Smith, Qing Dong, Victoria Feher, Zhe Nie
  • SUBSTITUTED ISOINDOLINONES AS MODULATORS OF CEREBLON-MEDIATED NEO-SUBSTRATE RECRUITMENT
    Publication number: 20230045737
    Abstract: Disclosed herein are isoindolinone compounds and methods for binding cereblon and for modulating cereblon neosubstrates. The isoindolinone compounds can have a structure of Formula (I).
    Type: Application
    Filed: December 5, 2019
    Publication date: February 9, 2023
    Inventors: Robert HUBBARD, Betty LAM, Shota KIKUCHI, Flora HUYNH, Chung-Mao PAN, Dan BEISNER, Eric ALLEN
  • AZOLE-FUSED PYRIDAZIN-3(2H)-ONE DERIVATIVES
    Publication number: 20230028114
    Abstract: Disclosed are compounds of Formula (1) and pharmaceutically acceptable salts thereof, wherein ?, ?, n, R4, R5, R6, R8, R9, R10, R11, X1, X2, X3 and X7 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula (1), to pharmaceutical compositions comprising them, and to their use for treating diseases, disorders, and conditions associated with GPR139.
    Type: Application
    Filed: September 15, 2020
    Publication date: January 26, 2023
    Inventors: Holger MONENSCHEIN, Sean MURPHY, Scott OLSEN, Natasha O'ROURKE, Holly REICHARD, Melinda DAVIS, Betty LAM
  • FUSED HETEROAROMATIC PYRROLIDINONES
    Publication number: 20220306634
    Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein G, L1, L2, R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, pharmaceutical compositions containing them, and their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other disorders, diseases, and conditions for which inhibition of SYK is indicated.
    Type: Application
    Filed: June 21, 2019
    Publication date: September 29, 2022
    Inventors: Yasuyoshi Arikawa, Benjamin Jones, Betty Lam, Masashi Takahashi, Christopher Smith, Qing Dong, Victoria Feher, Zhe Nie
  • 4-oxo-3,4-dihydro-1,2,3-benzotriazine modulators of GPR139
    Patent number: 11173161
    Abstract: The present invention provides a method for treating a disease, disorder or condition associated with GPR139 using compounds of formula 1: which are agonists of GPR139, certain compounds encompassed by formula 1, pharmaceutical compositions thereof, processes for making the compounds, and intermediates thereof.
    Type: Grant
    Filed: January 2, 2020
    Date of Patent: November 16, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Stephen Hitchcock, Betty Lam, Holger Monenschein, Holly Reichard
  • 4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINE MODULATORS OF GPR139
    Publication number: 20200129518
    Abstract: The present invention provides a method for treating a disease, disorder or condition associated with GPR139 using compounds of formula 1: which are agonists of GPR139, certain compounds encompassed by formula 1, pharmaceutical compositions thereof, processes for making the compounds, and intermediates thereof.
    Type: Application
    Filed: January 2, 2020
    Publication date: April 30, 2020
    Inventors: Stephen Hitchcock, Betty Lam, Holger Monenschein, Holly Reichard
  • 4-oxo-3,4-dihydro-1,2,3-benzotriazine modulators of GPR139
    Patent number: 10561662
    Abstract: The present invention provides a method for treating a disease, disorder or condition associated with GPR139 using compounds of formula 1: which are agonists of GPR139, certain compounds encompassed by formula 1, pharmaceutical compositions thereof, processes for making the compounds, and intermediates thereof.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: February 18, 2020
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Stephen Hitchcock, Betty Lam, Holger Monenschein, Holly Reichard
  • Pyrazines as modulators of GPR6
    Patent number: 10273225
    Abstract: The present invention provides compounds of formula I: which are useful as modulators of GPR6, pharmaceutical compositions thereof, methods for treatment of conditions associated with GPR6, processes for making the compounds and intermediates thereof.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: April 30, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Mark E. Adams, Jason W. Brown, Stephen Hitchcock, Maria Hopkins, Shota Kikuchi, Betty Lam, Holger Monenschein, Holly Reichard, Huikai Sun
  • 4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINE MODULATORS OF GPR139
    Publication number: 20190070187
    Abstract: The present invention provides a method for treating a disease, disorder or condition associated with GPR139 using compounds of formula 1: which are agonists of GPR139, certain compounds encompassed by formula 1, pharmaceutical compositions thereof, processes for making the compounds, and intermediates thereof.
    Type: Application
    Filed: November 2, 2018
    Publication date: March 7, 2019
    Inventors: Stephen Hitchcock, Betty Lam, Holger Monenschein, Holly Reichard
  • 4-OXO-3,4-dihydro-1,2,3-benzotriazine modulators of GPR139
    Patent number: 10159677
    Abstract: The present invention provides a method for treating a disease, disorder or condition associated with GPR139 using compounds of formula 1: which are agonists of GPR139, certain compounds encompassed by formula 1, pharmaceutical compositions thereof, processes for making the compounds, and intermediates thereof.
    Type: Grant
    Filed: August 22, 2017
    Date of Patent: December 25, 2018
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Stephen Hitchcock, Betty Lam, Holger Monenschein, Holly Reichard
  • PYRAZINES MODULATORS OF GPR6
    Publication number: 20180258073
    Abstract: The present invention provides compounds of formula I: which are useful as modulators of GPR6, pharmaceutical compositions thereof, methods for treatment of conditions associated with GPR6, processes for making the compounds and intermediates thereof.
    Type: Application
    Filed: May 14, 2018
    Publication date: September 13, 2018
    Inventors: Mark E. Adams, Jason W. Brown, Stephen Hitchcock, Maria Hopkins, Shota Kikuchi, Betty Lam, Holger Monenschein, Holly Reichard, Huikai Sun
  • Pyrazines as modulators of GPR6
    Patent number: 10000468
    Abstract: The present invention provides compounds of formula I: which are useful as modulators of GPR6, pharmaceutical compositions thereof, methods for treatment of conditions associated with GPR6, processes for making the compounds and intermediates thereof.
    Type: Grant
    Filed: February 13, 2015
    Date of Patent: June 19, 2018
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Mark E. Adams, Jason W. Brown, Stephen Hitchcock, Maria Hopkins, Shota Kikuchi, Betty Lam, Holger Monenschein, Holly Reichard, Huikai Sun
  • FUSED HETEROAROMATIC PYRROLIDINONES
    Publication number: 20180141951
    Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein G, L1, L2, R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, pharmaceutical compositions containing them, and their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other disorders, diseases, and conditions for which inhibition of SYK is indicated.
    Type: Application
    Filed: August 21, 2017
    Publication date: May 24, 2018
    Inventors: Yasuyoshi Arikawa, Benjamin Jones, Betty Lam, Masashi Takahashi, Christopher Smith, Qing Dong, Victoria Feher, Zhe Nie
  • 4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINE MODULATORS OF GPR139
    Publication number: 20170348319
    Abstract: The present invention provides a method for treating a disease, disorder or condition associated with GPR139 using compounds of formula 1: which are agonists of GPR139, certain compounds encompassed by formula 1, pharmaceutical compositions thereof, processes for making the compounds, and intermediates thereof.
    Type: Application
    Filed: August 22, 2017
    Publication date: December 7, 2017
    Inventors: Stephen Hitchcock, Betty Lam, Holger Monenschein, Holly Reichard
  • SUBSTITUTED 6-AZA-ISOINDOLIN-1-ONE DERIVATIVES
    Publication number: 20170327497
    Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein G, p, R1, R2, R3a, R4, and R5 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, cancer, and other disorders, diseases, and conditions for which inhibition of SYK is indicated.
    Type: Application
    Filed: May 18, 2017
    Publication date: November 16, 2017
    Inventors: Mark E. Adams, Rongliang Chen, Betty Lam, Matthew Lardy, Srinivasa Reddy Natala, Steven James Wilkens, Mitsunori Kono, Zhe Nie
  • 4-OXO-3,4-dihydro-1,2,3-benzotriazine as modulators of GPR139
    Patent number: 9770450
    Abstract: The present invention provides a method for treating a disease, disorder or condition associated with GPR139 using compounds of formula 1: which are agonists of GPR139, certain compounds encompassed by formula 1, pharmaceutical compositions thereof, processes for making the compounds, and intermediates thereof.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: September 26, 2017
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Stephen Hitchcock, Betty Lam, Holger Monenschein, Holly Reichard
  • PYRAZINES MODULATORS OF GPR6
    Publication number: 20170174659
    Abstract: The present invention provides compounds of formula I: which are useful as modulators of GPR6, pharmaceutical compositions thereof, methods for treatment of conditions associated with GPR6, processes for making the compounds and intermediates thereof.
    Type: Application
    Filed: February 13, 2015
    Publication date: June 22, 2017
    Inventors: Mark E. Adams, Jason W. Brown, Stephen Hitchcock, Maria Hopkins, Shota Kikuchi, Betty Lam, Holger Monenschein, Holly Reichard, Huikai Sun
  • 4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINE AS MODULATORS OF GPR139
    Publication number: 20170095480
    Abstract: The present invention provides a method for treating a disease, disorder or condition associated with GPR139 using compounds of formula 1: which are agonists of GPR139, certain compounds encompassed by formula 1, pharmaceutical compositions thereof, processes for making the compounds, and intermediates thereof.
    Type: Application
    Filed: December 16, 2016
    Publication date: April 6, 2017
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Stephen Hitchcock, Betty Lam, Holger Monenschein, Holly Reichard